212 related articles for article (PubMed ID: 21718248)
21. Carvedilol, a novel vasodilating beta-blocker with the potential for cardiovascular organ protection.
Feuerstein GZ; Ruffolo RR
Eur Heart J; 1996 Apr; 17 Suppl B():24-9. PubMed ID: 8733068
[TBL] [Abstract][Full Text] [Related]
22. Carvedilol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders.
Dunn CJ; Lea AP; Wagstaff AJ
Drugs; 1997 Jul; 54(1):161-85. PubMed ID: 9211087
[TBL] [Abstract][Full Text] [Related]
23. Protective effects of carvedilol against anthracycline-induced cardiomyopathy.
Kalay N; Basar E; Ozdogru I; Er O; Cetinkaya Y; Dogan A; Inanc T; Oguzhan A; Eryol NK; Topsakal R; Ergin A
J Am Coll Cardiol; 2006 Dec; 48(11):2258-62. PubMed ID: 17161256
[TBL] [Abstract][Full Text] [Related]
24. Carvedilol prevents and reverses hypertrophy-induced cardiac dysfunction.
Barone FC; Willette RN; Nelson AH; Ohlstein EH; Brooks DP; Coatney RW
Pharmacology; 2007; 80(2-3):166-76. PubMed ID: 17551266
[TBL] [Abstract][Full Text] [Related]
25. Carvedilol improves energy production during acute global myocardial ischaemia.
Monteiro P; Duarte AI; Moreno A; Gonçalves LM; Providência LA
Eur J Pharmacol; 2003 Dec; 482(1-3):245-53. PubMed ID: 14660029
[TBL] [Abstract][Full Text] [Related]
26. Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro.
Spallarossa P; Garibaldi S; Altieri P; Fabbi P; Manca V; Nasti S; Rossettin P; Ghigliotti G; Ballestrero A; Patrone F; Barsotti A; Brunelli C
J Mol Cell Cardiol; 2004 Oct; 37(4):837-46. PubMed ID: 15380674
[TBL] [Abstract][Full Text] [Related]
27. Carvedilol in heart mitochondria: protonophore or opener of the mitochondrial K(ATP) channels?
Oliveira PJ; Rolo AP; Sardão VA; Coxito PM; Palmeira CM; Moreno AJ
Life Sci; 2001 Jun; 69(2):123-32. PubMed ID: 11441902
[TBL] [Abstract][Full Text] [Related]
28. Nonselective beta-adrenergic blockade with carvedilol does not hinder the benefits of exercise training in patients with congestive heart failure.
Demopoulos L; Yeh M; Gentilucci M; Testa M; Bijou R; Katz SD; Mancini D; Jones M; LeJemtel TH
Circulation; 1997 Apr; 95(7):1764-7. PubMed ID: 9107160
[TBL] [Abstract][Full Text] [Related]
29. Honokiol, an activator of Sirtuin-3 (SIRT3) preserves mitochondria and protects the heart from doxorubicin-induced cardiomyopathy in mice.
Pillai VB; Kanwal A; Fang YH; Sharp WW; Samant S; Arbiser J; Gupta MP
Oncotarget; 2017 May; 8(21):34082-34098. PubMed ID: 28423723
[TBL] [Abstract][Full Text] [Related]
30. Protective effects of carvedilol in the myocardium.
Feuerstein GZ; Bril A; Ruffolo RR
Am J Cardiol; 1997 Dec; 80(11A):41L-45L. PubMed ID: 9412541
[TBL] [Abstract][Full Text] [Related]
31. Yogurt Containing the Probacteria Lactobacillus acidophilus Combined with Natural Antioxidants Mitigates Doxorubicin-Induced Cardiomyopathy in Rats.
Abu-Elsaad NM; Abd Elhameed AG; El-Karef A; Ibrahim TM
J Med Food; 2015 Sep; 18(9):950-9. PubMed ID: 25590792
[TBL] [Abstract][Full Text] [Related]
32. Cardioprotective effects of rosuvastatin and carvedilol on delayed cardiotoxicity of doxorubicin in rats.
Kim YH; Park SM; Kim M; Kim SH; Lim SY; Ahn JC; Song WH; Shim WJ
Toxicol Mech Methods; 2012 Jul; 22(6):488-98. PubMed ID: 22455613
[TBL] [Abstract][Full Text] [Related]
33. A histamine H₂ receptor blocker ameliorates development of heart failure in dogs independently of β-adrenergic receptor blockade.
Takahama H; Asanuma H; Sanada S; Fujita M; Sasaki H; Wakeno M; Kim J; Asakura M; Takashima S; Minamino T; Komamura K; Sugimachi M; Kitakaze M
Basic Res Cardiol; 2010 Nov; 105(6):787-94. PubMed ID: 20852875
[TBL] [Abstract][Full Text] [Related]
34. Doxorubicin-Mediated Cardiotoxicity: Role of Mitochondrial Connexin 43.
Pecoraro M; Sorrentino R; Franceschelli S; Del Pizzo M; Pinto A; Popolo A
Cardiovasc Toxicol; 2015 Oct; 15(4):366-76. PubMed ID: 25552354
[TBL] [Abstract][Full Text] [Related]
35. Inhibitory effect of carvedilol in the high-conductance state of the mitochondrial permeability transition pore.
Oliveira PJ; Coxito PM; Rolo AP; Santos DL; Palmeira CM; Moreno AJ
Eur J Pharmacol; 2001 Feb; 412(3):231-7. PubMed ID: 11166286
[TBL] [Abstract][Full Text] [Related]
36. Dietary nitrate supplementation protects against Doxorubicin-induced cardiomyopathy by improving mitochondrial function.
Zhu SG; Kukreja RC; Das A; Chen Q; Lesnefsky EJ; Xi L
J Am Coll Cardiol; 2011 May; 57(21):2181-9. PubMed ID: 21596234
[TBL] [Abstract][Full Text] [Related]
37. The protective roles of nitric oxide and superoxide dismutase in adriamycin-induced cardiotoxicity.
Cole MP; Chaiswing L; Oberley TD; Edelmann SE; Piascik MT; Lin SM; Kiningham KK; St Clair DK
Cardiovasc Res; 2006 Jan; 69(1):186-97. PubMed ID: 16157314
[TBL] [Abstract][Full Text] [Related]
38. Doxorubicin-induced cardiotoxicity: from bioenergetic failure and cell death to cardiomyopathy.
Carvalho FS; Burgeiro A; Garcia R; Moreno AJ; Carvalho RA; Oliveira PJ
Med Res Rev; 2014 Jan; 34(1):106-35. PubMed ID: 23494977
[TBL] [Abstract][Full Text] [Related]
39. β-Blocker carvedilol protects cardiomyocytes against oxidative stress-induced apoptosis by up-regulating miR-133 expression.
Xu C; Hu Y; Hou L; Ju J; Li X; Du N; Guan X; Liu Z; Zhang T; Qin W; Shen N; Bilal MU; Lu Y; Zhang Y; Shan H
J Mol Cell Cardiol; 2014 Oct; 75():111-21. PubMed ID: 25066695
[TBL] [Abstract][Full Text] [Related]
40. Pleiotropic effects of the beta-adrenoceptor blocker carvedilol on calcium regulation during oxidative stress-induced apoptosis in cardiomyocytes.
Wang R; Miura T; Harada N; Kametani R; Shibuya M; Fukagawa Y; Kawamura S; Ikeda Y; Hara M; Matsuzaki M
J Pharmacol Exp Ther; 2006 Jul; 318(1):45-52. PubMed ID: 16611853
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
